Hansa Biopharma — September 2023
-
HANSA BIOPHARMA: CARNEGIE MÄKLAT POST OM 1,5% INBÖRDES
STOCKHOLM (Nyhetsbyrån Direkt) Carnegie mäklade klockan 12.47 på måndagen en storpost motsvarande 1,5 procent av aktierna i Hansa Biopharma.
Det framgår av Infronts avslutsstatistik.Posten omfattade 799.749 aktier som mäklades till kursen 40:35 kronor.
-
Især GBS-data er næste større kurstrigger ...
"Guillain-Barré Syndrome (GBS): First high-level data read-out expected H2 2023."
Hansa Biopharma half year report 2023
/PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and...
(www.prnewswire.com)
-
Måske lidt positive toner om fremtiden fra en Scientist på Hansa Biopharma? https://www.linkedin.com/posts/louise-cornmark-phd-20439324_cartcelltherapy-immunotherapy-celltherapy-activity-7105051527412617216-RX_b?trk=public_profile_like_view
-
CARNEGIE MÄKLAT POST OM 1,5% INBÖRDES https://www.placera.se/placera/telegram/2023/09/11/hansa-biopharma-carnegie-maklat-post-om-15-inbordes.html
-
Vi är glada att kunna meddela att Erik Penser Bank den 14 september 2023 kommer att arrangera ännu en upplaga av vårt uppskattade evenemang Penser South i Malmö.
Deltagande bolag är Clemondo, Advanced Soltech, Candles Scadinavia, EQL Pharma, Hansa Biopharma..https://www.linkedin.com/events/pensersouth7098227348377890817/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind